Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06283966 · ClinicalTrials.gov registry record · Phase 3

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

A Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
5,000
Enrollment target
20
Study locations

NCT06283966 is a Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 5,000 participants, above the 179-participant average among 9 other COPD (Chronic Obstructive Pulmonary Disease) trials with a reported enrollment target (2693% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06283966, a Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
5,000 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Conditions Studied

COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • DRUG BGF MDI 320/14.4/9.6 μg
  • DRUG GFF MDI 14.4/9.6 μg

Study Locations (20)

Arizona

  • Research Site - Gilbert
  • Research Site - Glendale
  • Research Site - Mesa
  • Research Site - Mesa
  • Research Site - Phoenix
  • Research Site - Tempe
  • Research Site - Tempe
  • Research Site - Tucson
  • Research Site - Tucson

Alabama

  • Research Site - Athens
  • Research Site - Cullman
  • Research Site - Fairhope
  • Research Site - Huntsville
  • Research Site - Mobile
  • Research Site - Sheffield

California

  • Research Site - Apple Valley
  • Research Site - Canoga Park
  • Research Site - Castroville
  • Research Site - Garden Grove
  • Research Site - Gardena

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2024-02-21
Est. Completion 2028-03-07
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06283966

The ClinicalTrials.gov registry entry for NCT06283966 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 9 other COPD (Chronic Obstructive Pulmonary Disease) trials with a reported enrollment target (2693% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COPD (Chronic Obstructive Pulmonary Disease) appearing as the primary indexed condition, and to 2 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.

NCT06283966 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06283966 about?

NCT06283966 is a clinical study titled "A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease". This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

What is the current status of trial NCT06283966?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,000 participants. The study started on 2024-02-21. Estimated completion is 2028-03-07.

What conditions does trial NCT06283966 study?

This clinical trial studies the following conditions: COPD (Chronic Obstructive Pulmonary Disease).

What interventions are being tested in trial NCT06283966?

The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), GFF MDI 14.4/9.6 μg (DRUG).

Who is sponsoring clinical trial NCT06283966?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06283966 being conducted?

This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COPD (Chronic Obstructive Pulmonary Disease)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COPD (Chronic Obstructive Pulmonary Disease)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.